ArticleLa Radiologia medica2026
Can the new combined CEUS-BI-RADS score (CB score) reduce the number of breast false positive biopsies? Results from a monocentric study.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to develop a new contrast-enhanced ultrasound (CEUS)-based scoring system to distinguish between benign and malignant lesions and to evaluate its potential in obviating unnecessary ultrasound-guided breast biopsies.
methodsBetween November 2019 and June 2023, women with newly diagnosed breast lesions (BI-RADS 4a-c and 5) scheduled for ultrasound-guided biopsy and who underwent CEUS were retrospectively included. Two independent readers (one highly experienced breast radiologist with > 10 years of experience in breast imaging and one in training with > 3 years of experience) assessed all CEUS studies qualitatively in terms of time and intensity of enhancement compared with surrounding tissue, enhancement pattern and size increase after contrast administration, assigning a CEUS score. Further, a combined BI-RADS and CEUS score (CB score) was obtained. Descriptive statistics, AUC (area under the curve), receiver operating characteristic (ROC) analysis, sensitivity and specificity were used to investigate the diagnostic performance of this combined approach.
resultsA total of 294 lesions in 289 women (mean age 59.8 years; age range 23-88) were analyzed. The average lesion size was 16.6 ± 13.7 mm. Of these, 149 were malignant and 146 benign. CB score showed the highest diagnostic performance compared to CEUS score alone (average AUC = 0.935 vs. 0.890, respectively; p < 0.0001). For the more experienced reader, CB score yielded an AUC of 0.947; for the less experienced reader, AUC was 0.922. Finally, CB score would have obviated up to 40% of unnecessary biopsies.
conclusionThe combined CEUS and BI-RADS scoring system (CB score) improved diagnostic performance for breast cancer classification and showed high accuracy and consistency across readers with different experience, reducing the rate of unnecessary biopsies.
Indexed as
Identifiers
41569508What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.